Example: Heart Attack

Clinical Trials on Bacterial Infections

Total 4954 results

NCT01485705

Completed

Retrospective Examination of Initial Care of Severe Bacterial Infections of the Child

Conditions: Bacterial Infection
NCT04550767

Completed

: Bacterial Infections in Injecting Drug Users

Conditions: Bacterial Infection
NCT02858700

Completed

Value for Cord Blood Procalcitonin to Diagnose Early Neonatal Bacterial Infection

Conditions: Neonatal Bacterial Infection
NCT02688790

Terminated

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

Conditions: Bacterial Infections
NCT02794831

Completed

Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections

Conditions: Bacterial Infection
NCT03780140

Approved for marketing

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Conditions: Bacterial Infections
NCT02848534

Completed

The Value of the Neutrophil to Lymphocyte Ratio in the Diagnosis of Bacterial Infections

Conditions: Bacterial Infections
NCT02687906

Recruiting

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Conditions: Bacterial Infections
NCT00945087

Unknown status

Experimental Phage Therapy of Bacterial Infections

Conditions: Bacterial Infections
NCT02452047

Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Conditions: Bacterial Infections
NCT01173575

Completed

Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection

Conditions: Bacterial Infection
NCT02134301

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Conditions: Gram Positive Bacterial Infections
NCT00678106

Completed

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Conditions: Bacterial Infections
NCT03969901

Recruiting

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Conditions: Suspected or Documented Gram-negative Bacterial Infection
NCT03225079

Recruiting

PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring

Conditions: Severe Bacterial Infection
NCT02760745

Unknown status

Fever and Shivering: Frequency and Role in Predicting Serious Bacterial Infection

Conditions: Febrile Shivering; Severe Bacterial Infection
NCT00800488

Completed

Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months

Conditions: Fever; Bacterial Infection
NCT03696550

Recruiting

A Safety and PK Study of IV Eravacycline

Conditions: Bacterial Infections
NCT02268279

Completed

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

Conditions: Bacterial Infection
NCT01159470

Unknown status

The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children

Conditions: Bacterial Infections; Viral Infection
NCT01966055

Completed

Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents

Conditions: Bacterial Infections
NCT01946568

Completed

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Conditions: Bacterial Infections.
NCT02311816

Completed

Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients

Conditions: Bacterial Infection
NCT02750761

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Conditions: Gram-Positive Bacterial Infections
NCT02214433

Completed

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Conditions: Bacterial Infections